The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.
In a prespecified secondary analysis of the EMPEROR-Preserved trial of patients with HFpEF, researchers found that while the effect of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) did not vary by MRA use for the primary outcome of CV death and HF hospitalization, the benefit of empagliflozin to reduce first and recurrent HF hospitalizations was more pronounced in
Mineralocorticoid receptor antagonist use does not affect empagliflozin benefit in HFpEF
The benefit of the SGLT2 inhibitor empagliflozin in patients with HF with preserved ejection fraction did not differ between those who did or did not receive mineralocorticoid receptor antagonists, researchers reported.
In a prespecified secondary analysis of the EMPEROR-Preserved trial of patients with HFpEF, researchers found that while the effect of empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) did not vary by MRA use for the primary outcome of CV death and HF hospitalization, the benefit of empagliflozin to reduce first and recurrent HF hospitalizations was more pronounced in